Sydney Stern

Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial

Plain Language SummaryWhat is this summary about?This summary describes the main findings of the MANEUVER clinical trial for pimicotinib, a once-daily treatment. The goal was to see if pimicotinib could significantly reduce tumor size after 24 weeks of treatment in clinical trial...

Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm that significantly impacts patients’ quality of life through pain and swelling of the affected joint, resulting in limited range of motion. TGCT is categorized into two radiographic subtypes (localized an...